Lupus

Alfred Kim talks about the initial promise of hydroxychloroquine for COVID-19 and why it did not stand up to later scrutiny (13:06).

Among patients with systemic lupus erythematosus receiving treatment with hydroxychloroquine, low drug levels in the blood are associated with an elevated risk for arterial and venous thrombosis events, researchers report.

BIIB059, a monoclonal antibody that binds blood dendritic cell antigen 2 and inhibits interferon 1, improves total active joint count at 24 weeks in patients with systemic lupus erythematosus, findings from the LILAC trial show.

Click through for more details on this approval

Having COVID-19 is associated with an increased risk for flare among Latino patients with rheumatic diseases, researchers report.

Click through for more information on this announcement